Rocket Pharmaceuticals Inc at Needham Healthcare Conference (Virtual) Transcript
Good morning, everyone, and thank you for joining us this morning at the Needham & Company conference. My name is Gil Blum and I'm a senior biotech analyst here at Needham & Company covering the gene therapy space.
It is my pleasure to have with me today Dr. Gaurav Shah, Rocket Pharma's CEO. (Conference Instructions)
Questions & Answers
So maybe it's a good place to start as an introduction. I mean, investors have become kind of sanguine on gene therapy as of late. So do you think that potential for larger population drug approvals -- there is a filing for SRP-9001 in DMD and Exa-Cel in SCT, and your own drug in Danon disease. Do you think that could change sentiment?
Good to see you again. Thanks for having us this year. I think it will potentially change sentiment. I think there was a time when gene therapy was a platform that was very exciting,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
